Care after pancreatic resection according to an algorithm for early detection and minimally invasive management of pancreatic fistula versus current practice (PORSCH-trial): design and rationale of a nationwide stepped-wedge cluster-randomized trial by Smits, F.J. (F Jasmijn) et al.
STUDY PROTOCOL Open Access
Care after pancreatic resection according to
an algorithm for early detection and
minimally invasive management of
pancreatic fistula versus current practice
(PORSCH-trial): design and rationale of a
nationwide stepped-wedge cluster-
randomized trial
F. Jasmijn Smits1 , Anne Claire Henry1, Casper H. van Eijck2, Marc G. Besselink3, Olivier R. Busch3, Mark Arntz4,
Thomas L. Bollen5, Otto M. van Delden6, Daniel van den Heuvel5, Christiaan van der Leij7, Krijn P. van Lienden6,
Adriaan Moelker8, Bert A. Bonsing9, Inne H. M. Borel Rinkes1, Koop Bosscha10, R. M. van Dam11,
Sebastiaan Festen12, B. Groot Koerkamp2, Erwin van der Harst13, Ignace H. de Hingh14, Geert Kazemier15,
Mike Liem16, B. Marion van der Kolk17, Vincent E. de Meijer18, Gijs A. Patijn19, Daphne Roos20,
Jennifer M. Schreinemakers21, Fennie Wit22, C. Henri van Werkhoven23, I. Quintus Molenaar1†,
Hjalmar C. van Santvoort1*† and for the Dutch Pancreatic Cancer Group
Abstract
Background: Pancreatic resection is a major abdominal operation with 50% risk of postoperative complications. A
common complication is pancreatic fistula, which may have severe clinical consequences such as postoperative bleeding,
organ failure and death. The objective of this study is to investigate whether implementation of an algorithm for early
detection and minimally invasive management of pancreatic fistula may improve outcomes after pancreatic resection.
Methods: This is a nationwide stepped-wedge, cluster-randomized, superiority trial, designed in adherence to the
Consolidated Standards of Reporting Trials (CONSORT) guidelines. During a period of 22months, all Dutch centers
performing pancreatic surgery will cross over in a randomized order from current practice to best practice according to the
algorithm. This evidence-based and consensus-based algorithm will provide daily multilevel advice on the management of
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patients after pancreatic resection (i.e. indication for abdominal imaging, antibiotic treatment, percutaneous drainage and
removal of abdominal drains). The algorithm is designed to aid early detection and minimally invasive step-up management
of postoperative pancreatic fistula. Outcomes of current practice will be compared with outcomes after implementation of
the algorithm. The primary outcome is a composite of major complications (i.e. post-pancreatectomy bleeding, new-onset
organ failure and death) and will be measured in a sample size of at least 1600 patients undergoing pancreatic resection.
Secondary endpoints include the individual components of the primary endpoint and other clinical outcomes, healthcare
resource utilization and costs analysis. Follow up will be up to 90 days after pancreatic resection.
Discussion: It is hypothesized that a structured nationwide implementation of a dedicated algorithm for early detection and
minimally invasive step-up management of postoperative pancreatic fistula will reduce the risk of major complications and
death after pancreatic resection, as compared to current practice.
Trial registration: Netherlands Trial Register: NL 6671. Registered on 16 December 2017.
Background
Without treatment, survival in patients with pancreatic
cancer is only 4–6months. Pancreatic resection combined
with adjuvant chemotherapy can increase the median sur-
vival to 54months in selected patients with pancreatic
cancer [1]. Pancreatic resection is, however, a major ab-
dominal operation that is associated with a 50% risk of
complications [2]. Complications are associated with post-
operative death and reduced long-term survival because
patients with a complicated postoperative course are often
unfit to receive adjuvant chemotherapy [3–5].
A common complication after pancreatic resection is
pancreatic fistula, in which there is leakage of pancreatic
juices into the abdominal cavity [6–9]. This complication is
potentially life threatening due to its association with other
complications. Leakage of pancreatic juices can lead to ves-
sel erosion, potentially causing major bleeding. Systemic
inflammation may result in sepsis, organ failure and death
[8]. A postoperative pancreatic fistula that necessitates a
change in postoperative management is regarded a “clinic-
ally relevant fistula” [10]. In a recent systematic review of
40 studies, clinically relevant pancreatic fistula occurred in
13% of patients after pancreatic resection [2]. A Dutch
study (2005–2013) demonstrated that mortality in patients
with severe pancreatic fistula remains as high as 18% [9].
In general, in-hospital mortality after pancreatoduode-
nectomy varies widely among Dutch centers (interquartile
range 0–8%). This variability appears to be explained by
differences in failure-to-rescue rates between centers (i.e.
mortality in patients with major postoperative complica-
tions) [11]. A recent multicenter propensity-score-matched
study by the Dutch Pancreatic Cancer Group identified
doubling of mortality after primary relaparotomy, as com-
pared with primary minimally invasive catheter drainage
for postoperative pancreatic fistula (36% vs. 14%, P = 0.007;
risk ratio 0.39; 95% confidence interval 0.20–0.75) [9].
Relaparotomy causes a major inflammatory response syn-
drome in patients who are already ill, which might induce
or aggravate multiple organ failure and possibly death [12].
As an alternative to relaparotomy, minimally invasive per-
cutaneous catheter drainage has been shown to be very ef-
fective in the majority of patients [9]. In daily practice,
however, both treatment strategies are still frequently per-
formed (primary catheter drainage 73%, primary relaparot-
omy 27%) with no change towards a more minimally
invasive management strategy [9]. This might be related to
the lack of (international) guidelines on postoperative pa-
tient monitoring and management of complications.
This trial is designed to investigate whether implemen-
tation of an algorithm for postoperative care focusing on
early detection and minimally invasive step-up manage-
ment of postoperative pancreatic fistula results in a
lower rate of major complications and death after pan-
creatic resection, as compared with current practice.
This trial will also evaluate the superiority of the algo-
rithm in other clinical outcomes, the number of patients
receiving chemotherapy, quality of life, healthcare
resource utilization and costs.
Methods
Trial design
This is a nationwide, stepped-wedge, cluster-randomized
trial in all centers of the Dutch Pancreatic Cancer
Group. The research team will implement the algorithm
for early detection and minimally invasive management
of pancreatic fistula to change professional behavior in
each hospital and therefore stepped-wedge cluster
randomization at center level will be performed. This
trial was designed in accordance with the Consolidated
Standards of Reporting Trials (CONSORT) guidelines
for stepped-wedge, cluster-randomized trials [13] and
the Standard Protocol Items: Recommendation for Inter-
ventional Trials (SPIRIT) guidelines for clinical trials
(Fig. 1) [14].
The stepped-wedge, cluster-randomized trial is a form
of cross-over design with unidirectional cross-over (from
control to intervention phase) at different time points
for each cluster (Fig. 2). Each cluster will contain one
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center. Randomization will determine the order in
which each center will undergo the transition [15, 16].
In the first timeframe, all centers will deliver current
practice (i.e. control). In the second timeframe, the cen-
ter in the first cluster will start with algorithm-based
best practice (i.e. intervention), while all other centers
will still deliver current practice. In the third timeframe,
the second cluster will implement the algorithm. Fol-
lowing this approach, we proceed until all centers have
stepped over to the algorithm. In the last timeframe, all
centers will deliver treatment according to the algo-
rithm. Each cluster will contain one center; therefore,
the number of sequences is equal to the number of
participating centers and this will be 17. To ensure
adequate implementation of the algorithm, a wash-in
period was designed in which clinicians in the center
will be intensively trained by the research team on the
algorithm. To avoid contamination of centers still in
the current-practice phase, local clinicians will only
have access to the algorithm after cross-over to care
according to the algorithm.
Participants
Pancreatic surgery is centralized in The Netherlands in
centers performing at least 20 pancreatoduodenectomies
annually. All centers performing pancreatic surgery in
The Netherlands are participating in this trial. All
patients undergoing all types of pancreatic resection in
these centers are identified and will be recruited in this
trial. There are no exclusion criteria for centers or
patients (i.e. nationwide complete enumeration).
Data will be extracted from the prospective Dutch
Pancreatic Cancer Audit. Additional data on clinical out-
comes will be extracted prospectively through continu-
ous systematic evaluation of patient charts using a
predefined case record form. Data are stored on a cen-
tral secured data capturing tool (i.e. Castor EDC) con-
taining programmed checks for outliers. To ensure
patient confidentiality, the data stored centrally will be
cleaned to remove all information that could directly
trace back to an individual patient, and a unique patient
identifier number will be assigned to every patient. The
local principal investigator will have access to the
Fig. 1 Standard Protocol Items: Recommendation for Interventional Trials (SPIRIT) schedule of enrollment, interventions and assessments
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identifiable patient information. The data entered will be
checked by a senior researcher. Local principal investiga-
tors are responsible for data collection. They can
delegate this to the study personnel if resources are not
available at the center.
Withdrawal and replacement of centers
For the design of this trial it is essential that all partici-
pating centers participate for the entire duration of the
study, to prevent an unequal distribution of patients
across the two study arms (i.e. before and after imple-
mentation). If a center stops performing pancreatic sur-
gery during the study the randomization order will be
maintained. All patients treated in this center will still be
included in the final analysis, according to intention-to-
treat analysis. As all centers performing pancreatic
surgery in the Netherlands are participating in this trial,
centers will not be replaced after withdrawal.
Intervention
This trial evaluates a nationwide cluster-level interven-
tion in which all clinicians involved in the postoperative
care of patients undergoing pancreatic resection are
educated on the new algorithm for early detection and
minimally invasive management of postoperative pancre-
atic fistula. Currently, guidelines on how to diagnose
and manage postoperative pancreatic fistula are lacking.
This is concerning, since management of complications
appears to be the most important factor in decreasing
mortality after pancreatic resection. The algorithm is
based on findings in Dutch observational cohort studies,
comprehensive systematic literature analyses, an inven-
tory of current guidelines on postoperative care and
expert opinion. The impact of the proposed algorithm
was evaluated in a retrospective multicenter cohort and
consensus upon this algorithm was reached in several
plenary meetings with one pancreatic surgeon from each
of the centers of the Dutch Pancreatic Cancer Group.
The final algorithm was reviewed by the advisory com-
mittee of respected international experts from centers
performing a high volume of pancreatic resections
before implementation in this trial. As a result, we have
created a best-practice algorithm based on national and
international consensus. A complete overview of the
design and details on the content of the algorithm are
provided in Additional file 1: Appendix 1.
A schematic overview of the multilevel algorithm is
provided in Fig. 3. It is based on daily standardized
evaluation of all patients undergoing pancreatic resec-
tion from postoperative day 3 to discharge up to a max-
imum of 14 days. The algorithm will provide daily advice
on three decision levels: indication for abdominal com-
puted tomography (CT) scan (Fig. 4); indication for
(invasive) intervention (i.e. minimally invasive percutan-
eous drainage and/or antibiotic treatment) based on
evaluation of the abdominal CT scan (Fig. 5) and indica-
tion for removal of abdominal drain(s) (Fig. 6). The algo-
rithm includes clinical data from physical examination
and biochemical tests (i.e. systemic inflammatory re-
sponse syndrome (SIRS), C-Reactive protein (CRP),
white blood cell count (WBC), drain production includ-
ing amylase content and a daily consult from a pancre-
atic surgeon). At predefined, evidence-based cutoff
points (Fig. 4), an abdominal contrast-enhanced CT scan
and possibly subsequent minimally invasive intervention
should be performed or antibiotic treatment should be
started (Fig. 5). Each CT scan will be evaluated accord-
ing to predefined criteria (Fig. 5) to assess whether there
is suspicion of a pancreatic fistula and whether there is
an indication for minimally invasive percutaneous cath-
eter drainage. In the case of no clinical improvement
within 48 h after the last CT scan, a further CT scan
Fig. 2 Schematic overview of trial design
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should be performed to assess the indication for and
possibility of (additional invasive) intervention. The indi-
cation to remove abdominal drains will be evaluated
daily starting on postoperative day 3, for as long as there
are abdominal drains in place (Fig. 6). The interpretation
of the algorithm, the rationale behind the different pro-
posed cutoff points and the proposed management of
bleeding or hepaticojejunostomy leakage is provided in
Additional file 1: Appendix 2. Since we propose an inter-
vention of structured use of diagnostic and invasive in-
terventions that are already used in daily practice, no
additional harms to patients are introduced in this
study.
To facilitate clinical use of this complex algorithm, it
was incorporated in a smartphone application that
should be filled out daily for every patient. Access to this
application was granted to all clinicians participating in
the trial. The application will provide multilevel advice
based on the clinical and biochemical parameters en-
tered daily. The application will not contain information
that can be traced back to an individual patient. All data
will be stored on a secure central database that is access-
ible to the study coordinators 24 h a day, 7 days a week.
This was used to evaluate adherence to the study proto-
col. Local caregivers are contacted and reminded of the
application when it is not filled out for every patient in
the early afternoon, so that CT and potential drainage (if
indicated) can still be performed on the same day.
Since clinical decision-making on invasive intervention
in these patients is challenging, an expert panel is avail-
able to assess the indication for and feasibility of percu-
taneous drainage in the management of pancreatic
fistula. This online panel, consisting of dedicated radio-
logists with expertise in abdominal radiology, interven-
tional radiologists and surgeons with expertise in
pancreatic surgery, is available 24 h a day, 7 days a week.
The advice will be reported back to the clinician within
12 h after consultation or when at least three experts
provide their advice on the next step in the management
of these patients. The organization of this expert panel
will be similar to the Dutch Pancreatitis Study Group
expert panel [17].
Outcomes
All outcomes are assessed up to 90 days after the index
pancreatic resection or, if admission exceeds 90 days, up
to hospital discharge. All relevant definitions are pro-
vided in Table 1. The primary endpoint is a composite
of the following three major complications occurring
after study intervention:
Fig. 3 Schematic overview of algorithm. Schematic overview of the study algorithm. Daily evaluation starts on postoperative day (POD) 3 and includes
vital parameters (i.e. temperature, heart rate, respiratory rate), C-reactive protein (CRP), white blood cell count (WBC), drain production, drain amylase
level and a daily consult by a pancreatic surgeon. The algorithm will provide advice on three levels: indication of abdominal computed tomography
(CT) scan, removal of abdominal drain(s), indication for (invasive) intervention based on systematic evaluation of abdominal CT scan
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 New-onset postoperative bleeding requiring invasive
intervention
 New-onset organ failure (i.e. pulmonary, circulatory
or renal)
 Death
The rationale for this primary endpoint is that the pro-
posed algorithm for early detection and step-up manage-
ment of pancreatic fistula can possibly prevent clinical
deterioration. The most clinically severe complications
associated with pancreatic fistula are combined in this
endpoint [8]. Members of an adjudication committee
will individually asses the primary endpoint while
blinded to the assigned treatment arm; disagreements
will be resolved by consensus discussions, with alloca-
tion concealment.
Secondary endpoints include individual components
of the composite endpoint and an adapted version of
the primary endpoint in which only complications are
included that are deemed by the blinded adjudication
committee to be directly related to a pancreatic fistula.
Other secondary endpoints are: the Comprehensive
Complication Index (CCI) [25] based on complications
grade 3 or higher according to the Clavien-Dindo clas-
sification [19], postoperative pancreatic fistula [21],
gastroenterostomy leakage, postoperative bile leakage
[22], delayed gastric emptying [23], chyle leakage [26],
new-onset acute pancreatitis [24], number and timing
of abdominal CT scans, number, timing and type of in-
vasive (re-)interventions, admission to the Intensive
Care Unit (ICU), length of ICU stay, length of hospital
stay, readmission rate, number of patients receiving ad-
juvant chemotherapy at 90 day follow up, duration of
postoperative pancreatic fistula (time to removal of the
last abdominal drain or completion of pancreatectomy),
success of implementation (i.e. based on number and
timing of abdominal CT scans and proportion of pa-
tients’ days in which the algorithm was not followed).
Daily data on the incidence and duration of SIRS, sepsis
and organ failure (according to the definitions in Table
1 and according to Sequential Organ Failure Assess-
ment (SOFA) and the Multiple Organ Dysfunction
Score (MODS)) are also collected [27–29]. In addition,
we aim to evaluate the impact on quality of life, total
direct and indirect costs and budget impact (see “Eco-
nomic evaluation”).
Sample size calculation
The PORSCH trial is a superiority trial. The effect of the
intervention will be measured using the incidence of the
Fig. 4 Indication for computed tomography (CT) scan. Schematic overview of the indication for abdominal CT scan. °C, degrees Celsius; CRP, C-
reactive protein; mg, milligram; L, liter; H, hours; WBC, white blood cell count; M, minute
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Fig. 5 Evaluation of computed tomography (CT) scan. Schematic overview of the indication for (invasive) intervention based on systematic
evaluation of abdominal CT scan. °C, degrees Celsius; CRP, C-reactive protein; L, liter; h, hours; WBC, white blood cell count; m, minute
Fig. 6 Removal of abdominal drains. Schematic overview of the removal of abdominal drain(s). ml, milliliter
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primary endpoint (i.e. post-pancreatectomy bleeding,
new-onset organ failure or death), which is expected to
become lower after implementation of the algorithm. In
this study, we aim to improve the outcomes of all patients
undergoing pancreatectomy. However, to determine the
superiority of the algorithm in a homogenous sample of
patients, the sample size calculation was based on the co-
hort of patients undergoing pancreatoduodenectomy.
Table 1 Relevant definitions
New onset Not present any time in 24 h before study intervention; accounts for all outcomes
Mortality Rate of death occurring within 90 days after index pancreatic resection or, if index admission exceeds 90 days,
during admission
Organ failure [12]
Pulmonary PaO2 < 60 mmHg, despite FiO2 of 0.3, or need for mechanical ventilation
Circulatory Systolic blood pressure < 90mmHg, despite adequate fluid resuscitation, or need for inotropic support
Renal Creatinine level > 177 μmol/liter after rehydration or need for hemofiltration or hemodialysis
Post-pancreatectomy
hemorrhage (PPH)
Adapted from Wente et al [18]
Grade A Occurring < 24 h after pancreatectomy (early) with no therapeutic consequences
Grade B Both early (< 24 h) and late (> 24 h) requiring therapy (including fluid or blood transfusion and transfer to high-care
unit), with non-life-threatening clinical condition. Includes early PPH requiring relaparotomy
Grade C Occurring > 24 h after pancreatectomy (late) with severely impaired, life-threatening clinical condition requiring
intervention
Comprehensive Complication
Index (CCI)
This summarizes all postoperative complications, other than pre-existing complications, in a score from 0 (no com-
plications) to 100 (death). The CCI can be readily computed on the basis of tabulated complications according to
the Clavien-Dindo classification [19, 20]
Postoperative pancreatic fistula Amylase in drain fluid on or after postoperative day 3 of at least three times the upper level of normal serum
amylase [21]
Biochemical leak Requiring no change in postoperative management, hospital stay not prolonged
Grade B Persistent drainage > 3 weeks, change in postoperative management (i.e. catheter drainage, or angiographic
procedure for bleeding, signs of infection without organ failure, no relaparotomy), all related to pancreatic fistula
Grade C Grade B with reoperation, organ failure or death related to pancreatic fistula
Postoperative bile leakage Bilirubin in drain fluid on or after postoperative day 3 of at least three times the upper level of normal serum
bilirubin (adapted from Koch [22])
Delayed gastric emptying Adapted from Wente et al [23]
Grade A Nasogastric tube postoperative day 4–7 or need for replacement of tube after postoperative day 3; oral intake
between day 7 and 14
Grade B Nasogastric tube postoperative day 8–14 or need for replacement of tube after postoperative day 7; oral intake
between day 14 and 21
Grade C Nasogastric tube after postoperative day 14 or need for replacement of tube after postoperative day 14; oral intake
after day 14
Gastroenterostomy leakage As seen on abdominal imaging or during relaparotomy or secretion of fecal material from percutaneous drain or
through surgical wound
Acute pancreatitis Combination of abdominal pain, threefold increased amylase and lipase levels or as seen on radiologic imaging
[24]
New-onset diabetes mellitus Need for insulin or oral diabetes drugs within 3 months after discharge, not present before
pancreatoduodenectomy
Exocrine pancreatic
insufficiency
Need for oral pancreatic-enzyme supplementation within 3 months after discharge, not present before
pancreatoduodenectomy
Body mass index Weight in kilograms divided by the square of the height in meters
ASA American Society of Anesthesiologists classification
I Healthy patient without systemic disease
II Patient with mild systemic disease
III Patient with severe systemic disease, limiting activity but not life-threatening
PaO2 arterial partial pressure of oxygen, FiO2 fraction of inspired oxygen
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For sample size calculation we evaluated three Dutch
datasets: the mandatory Dutch Pancreatic Cancer Audit
(n = 1686), data from the study on management of pan-
creatic fistula (n = 309 patients [9]) and the validation
study performed in preparation for this trial (n = 174).
All outcome data used for sample size calculation are
presented in Table 2. The composite primary endpoint
occurred in 13.8% of patients in the Dutch cancer audit
(2014–2015), in 44% of patients with severe pancreatic
fistula after pancreatoduodenectomy [9] and in 17% in
our own validation database (2016). For sample size cal-
culation we used the lowest incidence that we identified
in these three datasets (i.e. 13.8% from the audit data).
The expected reduction in the composite primary end-
point was evaluated in two datasets. A relative reduction
of 53% was observed in the study on management of
pancreatic fistula (i.e. 34% after primary catheter drain-
age versus 73% after primary relaparotomy). Using the
Dutch Pancreatic Cancer Audit data, centers were di-
vided into four quartiles based on the incidence of the
primary endpoint after pancreatoduodenectomy. The in-
cidence was 21% in the worst-scoring quartile containing
292 patients from four centers. The incidence of the
composite primary endpoint was 8% (i.e. relative reduc-
tion 62%) in the best-scoring quartile containing 331 pa-
tients who underwent pancreatoduodenectomy in five
centers. Based on these outcomes, a relative reduction of
50% in the primary endpoint was used for the sample
size in the PORSCH trial. This was the minimal reduc-
tion deemed clinically relevant by the members of the
trial steering committee and stakeholders from the
Dutch Pancreatic Cancer Group.
The required sample size was calculated using the for-
mula for stepped-wedge designs using an expected inci-
dence of 13.8%, a relative reduction of 50%, two-sided
alpha of 0.05 and power of 0.80 [30]. The intra-cluster
correlation (ICC) estimated from the Dutch Pancreatic
Cancer Audit was 0.009 (95% CI 0.006–0.049). As the
within-period and between-period ICC were the same,
the cluster autocorrelation was set at 1 [31]. Table 3
provides the required sample size for different numbers
of participating sites (i.e. clusters). This number dictates
the inclusion time in this study design, which was based
on the total number of pancreatoduodenectomies per-
formed in the last 2 years according to the Dutch Pan-
creatic Cancer Audit. As each cluster will contain one of
the 17 participating centers, the number of sequences is
equal to the number of clusters. Based on the annual
number of pancreatoduodenectomies performed in The
Netherlands in 2014 and 2015, the planned study dur-
ation is 92 weeks to include the required sample size of
1186 pancreatoduodenectomies with complete enumer-
ation (i.e. 5.1 weeks per step for 18 time periods). The
total duration of the trial will be 96 weeks, including a 4-
week wash-in period.
As we include patients undergoing all types of pancre-
atic resection in this trial, the total number of patients
registered in this trial is expected to be 25% more than
the required sample size. We will perform the primary
analyses in patients undergoing pancreatoduodenectomy
and subsequently in all patients undergoing any type of
pancreatic resection.
Interim analysis
An interim analysis will be performed to evaluate the in-
clusion rate. At 50% of the planned time for inclusion,
the total number of inclusions will be evaluated. If the
sample size is less than 47.5% of the target at that time,
the duration of steps in the design for the remaining part
of the study will be prolonged such that power of 80% is
maintained. If the sample size is adjusted at interim ana-
lysis, the adjusted dates for cross-over will dictate the
allocation of patients to routine practice or best practice
for the analysis.
Safety reporting
No experimental interventions are introduced in this
trial. Therefore, no additional safety or health risks are
introduced for patients within this trial as compared to
Table 2 Composite primary endpoint
DPCA Management of pancreatic fistula Validation database
Year(s) 2014–2015 2005–2013 2016
Patients 1686 309 174
Composite primary endpoint 12% 44% 15%
In patients undergoing pancreatoduodenectomy 14% 44% 17%
In patients undergoing distal pancreatectomy 7% – 7%
Relative reduction between study groups – 53% –
Relative reduction between quartiles 62% – –
Incidence of the primary composite endpoint in three databases; “years” represents the time pancreatic resections were performed; “patients” represents the
number of patients included in the analysis. “Management of pancreatic fistula” refers to Smits et al. JAMA Surg [9]. and includes only patients with severe
pancreatic fistula; “validation study” refers to data used to validate the proposed algorithm
DPCA Dutch Pancreatic Cancer Audit
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regular care and therefore no specific safety monitoring
is performed.
Randomization, blinding and treatment allocation
Randomization is performed after obtaining consent for
participation in this trial from the principal investigator
and after approval from local (medical ethical) committees
of every participating center was obtained. Centers are
randomized by an independent statistician using R statis-
tics software to determine the timing of cross-over from
current practice to the algorithm [32]. Stratification at
randomization is applied for center volume (>45 vs. ≤ 45
pancreatic resections a year, median value based on data
from the Dutch Pancreatic Cancer Audit 2014–2015).
Local principal investigators are informed about the
allocated time of cross-over of their center, but are blinded
to the randomization sequence for all other centers. Blind-
ing of treatment strategy for clinicians or study personnel
is not feasible due to the study design. Primary outcomes
will be assessed by individual members of an adjudi-
cation committee blinded to the intervention (i.e.
whether this patient was treated before or after im-
plementation of the algorithm). Patients will be coded
by a numeric randomization key, and only the princi-
pal investigators have access to this key.
Statistical analysis
For statistical analysis, outcomes of all patients undergoing
pancreatic resection before implementation of the algo-
rithm (i.e. current practice) will be compared to outcomes
of all patients undergoing pancreatic resection after imple-
mentation of the algorithm (i.e. best practice). The date of
pancreatic resection will determine the study phase in
which a patient will be analyzed. The primary analysis will
be on an intention-to-treat basis according to the planned
date of cross-over to care according to the algorithm. Data
from patients in the wash-in period will be excluded from
the primary analysis. Secondary analyses include a per-
protocol analysis in which we will compare patients who
receive care according to the algorithm (i.e. all resections
after first implementation presentation at a center, includ-
ing patients undergoing pancreatic resection in the wash-
in period) to patients undergoing pancreatic resection
before cross-over. When appropriate, 95% confidence
intervals will be calculated. In all analyses a two-sided
value of alpha of 0.05 will be used to denote statistical
significance.
Missing baseline data will be imputed using multiple
imputation techniques. The primary analysis will be per-
formed using the multiple imputed data. A complete case
analysis will be performed to check for inconsistencies.
Baseline data will be analyzed and reported using standard
descriptive statistics. The chi-square or Fisher’s exact test
is used to compare categorical variables as appropriate.
Parametric continuous variables are presented as mean
with standard deviation (SD) and are compared using
Student’s t test. Non-parametric continuous variables are
presented as median with interquartile range (IQR) and
are compared using the Mann-Whitney U test.
The primary endpoint (i.e. composite of post-
pancreatectomy bleeding, new-onset organ failure and
death) is a binary variable that will be analyzed using
mixed-effects logistic regression analysis. Secondary end-
points will be analyzed using crude and adjusted mixed-
effects logistic regression analysis (for binary outcomes)
or mixed-effects linear regression analysis (for continu-
ous outcomes). Crude analysis will include a random
intercept and random slope at the level of the hospital
to adjust for the design, and no other covariates.
Adjusted analysis will additionally include the following
covariates: calendar time and time since cross-over as a
continuous variable, predictors for postoperative pancre-
atic fistula (i.e. soft pancreatic texture, small-diameter
pancreatic duct, increasing blood loss during pancreatic
resection and underlying disease that is not pancreatitis
or pancreatic adenocarcinoma [33]) and predictors for
the primary endpoint (i.e. male gender, increasing age,
American Society of Anesthesiologists (ASA) classifica-
tion > 2, index pancreatic resection pancreatoduodenect-
omy; based on multivariable logistic regression analysis
as presented in Table 4). Relevant model assumptions
(such as distribution of residuals) will be checked for all
models; if deviations from the analysis plan are required
this will be described. Crude and adjusted odds ratios
with 95% confidence interval and p value will be
reported.
Length of hospital stay will be calculated from the date
of the index pancreatic resection and will be analyzed
Table 3 Required sample size for different numbers of participating centers
Number of centers Cluster sizea Required sample size Expected inclusions Inclusion timeb
14 5.9 1239 1239 28
15 5.1 1220 1224 25
16 4.5 1204 1224 24
17 3.9 1186 1193 22
a Average number of patients per center for every step in the stepped-wedge design
b Inclusion time in months including 4 weeks wash-in phase
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using mixed-effects Cox proportional hazards regression,
using discharge alive as the outcome event. Patients who
die during the index hospitalization will be censored at
the day of death. Length of ICU stay and time to reso-
lution of pancreatic fistula (i.e. time to removal of the
last abdominal drain or completion of pancreatectomy)
will be analyzed using a zero-inflated negative binominal
regression model.
Subgroup and sensitivity analyses
Analyses will be performed both on the group of pa-
tients undergoing pancreatoduodenectomy and on the
entire group of all patients undergoing pancreatic resec-
tion. Additional subgroup analyses will be performed
based on adherence to the study protocol (i.e. propor-
tion of patients’ days in which the algorithm is followed),
hospital volume (> 45 vs. ≤ 45 pancreatic resections a
year), pathologic nature of disease (malignant disease),
in patients with postoperative pancreatic fistula and in
patients with a high risk of pancreatic fistula [34].
A sensitivity analysis will be performed to evaluate the
impact on outcomes related to postoperative pancreatic
fistula. To this aim, the adjudication will be asked if an
outcome was related to postoperative pancreatic fistula
and if this outcome could have been prevented by adher-
ence to the algorithm. Two separate analyses will be per-
formed on the Comprehensive Complication Index: one
analysis including all complications and one adjusted
analysis, in which interventions imposed by the algo-
rithm (e.g. minimal invasive catheter drainage and use of
antibiotic management for abdominal sepsis) will not be
included in the calculation. A sensitivity analysis will be
performed to evaluate the success of implementation.
Centers will be divided into equally sized clusters based
on the percentage of additional abdominal CT scans per
patient after implementation, as compared with before
implementation. Separate analysis will be performed for
each group.
Economic evaluation
A cost-effectiveness analysis will be performed to com-
pare the health effects and costs of treatment according
to the algorithm, as compared with current practice.
Preventing major complications is likely to be cost sav-
ing, for example, by preventing admission to the ICU
and decreasing the length of hospital stay. However,
additional costs may also be introduced by increasing
the need for diagnostic resources (e.g. biochemical tests
and CT scans) and possibly also minimally invasive in-
terventions. Therefore, it is important to assess whether
these costs will be counterbalanced by future health
effects and cost savings.
For calculation of cost-effectiveness from a healthcare
perspective, the volume of healthcare consumption will
be measured during the trial using an adapted version of
the Medical Consumption Questionnaire (iMCQ). This
Table 4 Factors associated with the composite primary endpoint in 1686 patients undergoing pancreatic resection in the Dutch
Pancreatic Cancer Audit
Outcome Univariable Multivariable
OR (95% CI) P value OR (95% CI) P value
Male gender 1.64 (1.20–2.23) 0.002 1.64 (1.19–2.27) 0.002
Age 1.02 (1.01–1.04) 0.003 1.02 (1.00–1.03) 0.04
BMI 1.00 (1.00–1.01) 0.52
ECOG performance score 0.17
2 vs. 1 1.29 (0.92–1.79) 0.14
3 vs. 1 1.59 (0.95–2.66) 0.08
4 vs. 1 0.44 (0.06–3.33) 0.43
ASA classification (3 and 4 vs. 1 and 2) 1.87 (1.33–2.61) < 0.001 1.79 (1.26–2.53) 0.001
Preoperative additional nutrition 0.05
Oral vs. none 0.98 (0.70–1.38) 0.91
Via nasogastric tube vs. none 1.74 (0.92–3.28) 0.90
Via TPN vs. none 4.04 (1.17–14.02) 0.03
Preoperative biliary drainage 0.97 (0.71–1.32) 0.82
Distal pancreatectomy vs. pancreatoduodenectomy 0.50 (0.31–0.79) 0.003 0.58 (0.36–0.94) 0.03
Texture pancreas (hard/firm vs. soft/normal) 1.22 (0.86–1.73) 0.26
Data from the Dutch Pancreatic Cancer Audit (2014–2015). Presented are the outcomes of univariable and multivariable logistic regression model showing
gender, age, American Society of Anesthesiologists (ASA) classification and type of index resection are independently associated with the occurrence of the
composite primary endpoint
OR odds ratio, BMI body mass index, ECOG Eastern Cooperative Oncology Group, TPN total parental nutrition
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questionnaire will measure healthcare utilization for
medical expenses both in hospital and out of hospital,
including but not limited to medication, invasive inter-
ventions, days in the hospital, outpatient visits after dis-
charge and visits to the general practitioner. Unit costs
will be derived from tariffs as described in the “Zorgin-
stituut Nederland Kostenhandleiding” [35]. Medication
costs will be derived from the “Zorginstituut Nederland
Medicijnkosten” and, if dosages are missing in the
iMCQ, standard dosages will be derived from the “Zor-
ginstituut Nederland Farmacotherapeutisch Kompas”.
For calculation of cost-effectiveness from a societal per-
spective, the Productivity Consumption Questionnaire
(iPCQ) will be used to derive losses in productivity.
Travel costs per individual will be calculated using aver-
age travel distances and standard tariffs from the Zorgin-
stituut Nederland Kostenhandleiding in combination
with the number of visits in the iMCQ. Health-related
quality of life will be measured using the Euroqol 5
dimensions-5 levels questionnaire (EQ5D-5 L) at base-
line and 90 days after pancreatic resection (i.e. end of
follow up) [36]. Relevant outcomes will be extracted
from case record forms and electronic health records at
the end of follow up. The quality-of-life scores related to
these outcomes will be derived from scientific literature
for calculation of cost-effectiveness. Quality-adjusted life
years (QALYs) will be calculated by multiplying the dur-
ation of time spent in a health state by the correspond-
ing quality-of-life score, hence combining life years and
quality of life.
Trial-based cost-effectiveness analysis (CEA) will be
performed using the empirical data comparing current
practice to best practice up to 90 days after the index
pancreatic resection [37]. Missing data on either health
effects or costs will be imputed using multiple imput-
ation. An additional model-based CEA will be performed
to extrapolate the trial results beyond the trial duration
[38–40], because the short-term effects from implemen-
tation of the algorithm - if present - are likely to affect
long-term outcomes as well. Besides having influence on
the primary outcome, implementation of best practice
might also influence the risk of pancreatic insufficiency
and possibly survival, as patients are in a better clinical
condition to receive adjuvant chemotherapy. Using
mathematical modeling, short-term evidence from the
PORSCH trial will be translated to more generic out-
comes, such as survival and health status. Finally, using
the mathematical model and additional evidence from
the literature, a cost-effectiveness analysis will be per-
formed calculating the long-term additional costs and
QALYs when implementing the algorithm for a lifetime
horizon.
The incremental cost effectiveness ratio (ICER) will be
calculated for both the trial-based and model-based CEA
by dividing the difference in costs between usual care
and the intervention by the difference in QALYs be-
tween usual care and the intervention. Sensitivity ana-
lysis will be performed on parameters that are expected
to have the largest uncertainty. Bootstrapping and prob-
abilistic sensitivity analysis will be performed in the trial-
based and model-based CEA, respectively, to determine
the uncertainty surrounding incremental health effects
and costs. Results from these uncertainty analyses will
be used to create (incremental) cost-effectiveness planes
to graphically represent these results [40]. Cost-
effectiveness acceptability curves will be calculated to
demonstrate the probability that the intervention strat-
egy will be cost-effective compared to current practice
when using a range of cost-effectiveness thresholds (i.e.
the amount society is willing to pay for an additional
QALY).
Discussion
In this study protocol we describe a nationwide,
stepped-wedge, cluster-randomized trial on the imple-
mentation of an algorithm focusing on early detection
and minimally invasive management of pancreatic fistula
after pancreatic resection. By implementation of this
algorithm, we expect a reduction in major complications
(i.e. bleeding and organ failure) and death, as compared
with current practice.
Several other studies aimed to improve the outcomes
by prevention or prediction of postoperative pancreatic
fistula [34, 41–43]. Although these studies have led to an
improved quality of care worldwide, pancreatic fistula
still remains one of the most feared complications after
pancreatic surgery. When not recognized early, pancre-
atic fistula may have a major impact on the clinical
course and is associated with an increased risk of in-
hospital death, prolonged in-hospital stay, lower chance
of receiving adjuvant chemotherapy and impaired long-
term survival [3, 5, 1]. A recent study showed that the
difference in clinical outcome in Dutch centers can be
explained by a difference in the failure-to-rescue rate ra-
ther than the incidence of major complications [11]. In
the Netherlands, pancreatic surgery is centralized in
high-volume centers (i.e. > 20 pancreatoduodenectomies
annually). Study initiatives are coordinated by the Dutch
Pancreatic Cancer Group, a multidisciplinary collabor-
ation aiming to improve the quality of care for patients
with pancreatic cancer in The Netherlands, including
this study. The stepped-wedge, cluster-randomized trial
is a relatively new concept to evaluate the implementa-
tion of best-practice interventions at a multicenter level;
several studies have had positive results [16, 44]. When
implemented nationally, this trial might improve clinical
outcomes at a nationwide level, and not only for selected
patients in high-volume centers.
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Leakage of pancreatic enzymes causes a local inflam-
matory response and thereby excretion of acute-phase
enzymes like C-reactive protein, release of white blood
cells and clinical signs of inflammation like fever, tachy-
cardia and tachypnea [45, 46]. Amylase levels might be
elevated when measured in abdominal drain fluid [10].
The abdominal drain might, however, not be in an ad-
equate position to drain pancreatic leakage. In addition,
abdominal drains are becoming more frequently omitted
at the time of pancreatic resection or are removed in the
early postoperative phase [47]. In these patients, signs of
inflammation are the only early signs of postoperative
pancreatic fistula. These signs are, however, nonspecific
and often not recognized as potential pancreatic leakage,
especially in centers where only a few patients with pan-
creatic fistula are seen annually [45]. We believe, how-
ever, that in these patients with a high risk of life-
threatening complications, early abdominal CT should
be performed and peripancreatic fluid collections should
be managed aggressively with percutaneous drainage in
patients showing signs of systemic inflammation [9, 48,
49]. This might result in an increased use of abdominal
imaging and percutaneous catheter drainage procedures
in the entire study population, with the intention of re-
ducing severe bleeding, organ failure or mortality in a
subset of patients. The outcomes of this trail will provide
more insight into the “number needed to scan” or “num-
ber needed to drain” and the cost-effectiveness of inten-
sified postoperative monitoring.
The management of pancreatic fistula after pancreatic
resection is shifting from relaparotomy to a more con-
servative approach using minimally invasive catheter
drainage. Pancreatic fistula after pancreatoduodenect-
omy leads to an intra-abdominal fluid collection filled
with activated pancreatic juices. When drained ad-
equately, even a severe pancreatic fistula could resolve
with primary catheter drainage alone [9]. In addition,
percutaneous drainage is a minimally invasive procedure,
which will provoke less surgical trauma (i.e. tissue injury
and systemic inflammatory response) compared with
relaparotomy. Even moderately small surgical trauma
that induces a proinflammatory cytokine response can
lead to organ failure in severely ill patients [12]. There
is, however, still a significant number of patients in
whom pancreatic fistula is managed primarily through
laparotomy. Clinical outcomes might be improved using
a step-up approach with primary catheter drainage and
relaparotomy as a salvage option in patients who
continue to deteriorate without further options for
minimally invasive drainage.
This trial has several limitations. Even though a
stepped-wedge, cluster-randomized trial is less efficient
as compared with a conventional individual randomized
trial, this is the only appropriate design to evaluate our
research question, which is based on education in “best
practice care” involving early detection and management
of pancreatic fistula. With a design based on individual-
level randomization, contamination of the control group
would have been very likely due to the learning effect of
applying the algorithm in the intervention group. The
more efficient, cluster-randomized, cross-over design, in
which half of the clusters crosses over from control to
intervention and the other from intervention to control,
is also prohibited due to the learning effect. Moreover, a
stepped-wedge design was also chosen for logistical rea-
sons, i.e. the aim is to implement the algorithm in all
Dutch pancreatic centers and it is not feasible to roll out
an education-based intervention with very active partici-
pation of the study team in more than one center simul-
taneously. Additionally, after calculating the statistical
efficiency, the power achieved from a stepped-wedge,
cluster-randomized trial was considerably higher than
that of a parallel cluster-randomized trial, which is due
to relatively high intra-cluster correlation.
Still, there is a risk that current practice will be con-
taminated by the proposed intervention in this study,
which would result in a bias towards no effect. To
truly evaluate the effect of the implementation of the
algorithm it is essential to minimize the risk of con-
tamination in the centers where patients are still being
treated according to current practice. If all clinicians
were intensively involved in the development of the al-
gorithm, they might adjust their current practice to
the algorithm before the start of the trial. On the
other hand, for optimal implementation it is essential
that the centers feel involved in the development of
the intervention. Therefore, the algorithm was de-
signed by a group of stakeholders of the Dutch Pan-
creatic Cancer Group. The proposed algorithm was
validated in a retrospective multicenter cohort, as pro-
spective implementation would have increased the risk
of contamination. Next, the algorithm was discussed at
a meeting with one leading surgeon with expertise in
pancreatic surgery from every participating center,
using a PowerPoint presentation, the content of which
was not shared with the audience electronically or on
paper. At this meeting, consensus was reached on the
content of the algorithm. The pancreatic surgeons
were instructed not to share with their colleagues what
was discussed during the meeting. The algorithm was
not distributed within the centers prior to the start of
the wash-in period. Consensus was reached on the
final algorithm with internationally respected experts
in the field of pancreatic surgery before nationwide
implementation in this trial. We believe this approach
will ensure local support for the intervention while
minimizing potential bias through knowledge of its
components.
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In conclusion, we have designed a stepped-wedge,
cluster-randomized trial to evaluate the effect of the na-
tionwide implementation of an algorithm for early detec-
tion and minimally invasive management of pancreatic
fistula after pancreatic resection on severe complications
and mortality in The Netherlands.
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Committees United (MEC-U) approved the study and
waived the need for informed consent (reference number
W17.057). Local approval for the study is obtained in all
participating centers before recruitment starts.
First inclusion: 8 January 2018.
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